"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
(Generic versions may still be available.)
- Patient Information:
Details with Side Effects
RAXAR Tablets contain grepafloxacin hydrochloride RAXAR (grepafloxacin) is a broad-spectrum fluoroquinolone antimicrobial agent for oral administration.
The chemical name for grepafloxacin is (±)-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl- 7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid monohydrochloride sesquihydrate. Its molecular formula is C19H22FN3O3HCl 3/2 H2O and it has a molecular weight of 422.88. It is soluble in water and very slightly soluble in ethanol.
RAXAR (grepafloxacin) Tablets are white to pale yellow, film-coated, biconvex, bevel-edged tablets containing either 200 mg, 400 mg, or 600 mg of grepafloxacin base, formulated as a hydrochloride salt. Each tablet contains the following inactive ingredients: low substituted hydroxypropyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose 2910, magnesium stearate, microcrystalline cellulose, talc, and titanium dioxide.
Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Raxar Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.